NO942912L - Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 - Google Patents

Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5

Info

Publication number
NO942912L
NO942912L NO942912A NO942912A NO942912L NO 942912 L NO942912 L NO 942912L NO 942912 A NO942912 A NO 942912A NO 942912 A NO942912 A NO 942912A NO 942912 L NO942912 L NO 942912L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
monoclonal antibody
human interleukin
cloning
expression
Prior art date
Application number
NO942912A
Other languages
English (en)
Norwegian (no)
Other versions
NO942912D0 (es
Inventor
Chuan-Chu Chou
Nicholas J Murgolo
John S Abrams
Chung-Her Jehn
Mary E Petro
Jon E Silver
Stephen Tindall
William T Windsor
Paul J Zavodny
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO942912D0 publication Critical patent/NO942912D0/no
Publication of NO942912L publication Critical patent/NO942912L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO942912A 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 NO942912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06
PCT/US1993/000759 WO1993016184A1 (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Publications (2)

Publication Number Publication Date
NO942912D0 NO942912D0 (es) 1994-08-05
NO942912L true NO942912L (no) 1994-10-06

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942912A NO942912L (no) 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (es)
EP (1) EP0625201A1 (es)
JP (2) JPH07505767A (es)
KR (2) KR0150060B1 (es)
CN (1) CN1077991A (es)
AR (1) AR248044A1 (es)
AU (1) AU683836B2 (es)
CA (1) CA2129445A1 (es)
CZ (1) CZ291039B6 (es)
FI (1) FI943635A0 (es)
HU (1) HUT67943A (es)
IL (1) IL104620A (es)
NO (1) NO942912L (es)
NZ (1) NZ249633A (es)
PL (1) PL176393B1 (es)
RU (1) RU94045919A (es)
SG (1) SG49597A1 (es)
SK (1) SK280610B6 (es)
TN (1) TNSN93012A1 (es)
WO (1) WO1993016184A1 (es)
ZA (1) ZA93779B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR248044A1 (es) 1992-02-06 1995-05-31 Schering Corp Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
ATE346867T1 (de) * 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
KR100259828B1 (ko) * 1995-09-11 2000-06-15 히라타 다다시 인체 인터루킨 5 수용체 알파-사슬에 대한 항체
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP2977470B1 (en) * 2002-10-16 2018-01-03 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101206318B1 (ko) 2004-10-28 2012-11-29 교와 핫꼬 기린 가부시키가이샤 자궁 내막증 치료제
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20100086554A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
CN102203286B (zh) * 2008-10-23 2013-07-17 弗·哈夫曼-拉罗切有限公司 免疫球蛋白编码核酸的测定
CN103429261A (zh) * 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
EA034864B1 (ru) 2014-09-08 2020-03-31 Сефалон, Инк. Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
EA037487B1 (ru) 2015-08-24 2021-04-02 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Биофармацевтические композиции
BR112019025736A2 (pt) 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
TWI801425B (zh) * 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
WO1990004979A2 (en) * 1988-11-03 1990-05-17 Schering Corporation Method of preventing or reducing eosinophilia
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
AR248044A1 (es) 1992-02-06 1995-05-31 Schering Corp Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.

Also Published As

Publication number Publication date
CZ291039B6 (cs) 2002-12-11
ZA93779B (en) 1993-08-05
FI943635A (fi) 1994-08-05
NO942912D0 (es) 1994-08-05
HU9402293D0 (en) 1994-10-28
EP0625201A1 (en) 1994-11-23
TNSN93012A1 (fr) 1994-03-17
RU94045919A (ru) 1996-11-10
KR950700413A (ko) 1995-01-16
FI943635A0 (fi) 1994-08-05
KR0150060B1 (ko) 1998-08-17
AU3656093A (en) 1993-09-03
SK280610B6 (sk) 2000-05-16
HUT67943A (en) 1995-05-29
IL104620A0 (en) 1993-06-10
SG49597A1 (en) 1998-06-15
SK91894A3 (en) 1995-02-08
CZ191094A3 (en) 1994-12-15
IL104620A (en) 2000-02-29
CN1077991A (zh) 1993-11-03
CA2129445A1 (en) 1993-08-07
NZ249633A (en) 1995-12-21
AR248044A1 (es) 1995-05-31
US6451982B1 (en) 2002-09-17
JP2000210097A (ja) 2000-08-02
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
AU683836B2 (en) 1997-11-27
JPH07505767A (ja) 1995-06-29

Similar Documents

Publication Publication Date Title
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
ATE208820T1 (de) Humanisierte antikoerper
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
WO1994004691A3 (en) Dimer and multimer forms of single chain polypeptides
PT100195A (pt) Anticorpos monoclonais quimericos e humanos que se ligam a epitopos de receptores de factor de crescimento da epiderme, seus vectores de expressao, processo de preparacao e composicoes farmaceuticas que os contem
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
DK1144006T3 (da) Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
NO962125L (no) Anti-idiotypiske antistoffer som induserer en immunrespons mot epidermal vekstfaktorreseptor
HUP9903273A3 (en) Anti-human mp52 monoclonal antibody

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application